|
**Overview**: Canavan Disease Panel**Introduction**: The Canavan Disease Panel is a diagnostic tool designed to screen for Canavan disease using whole blood samples. In India, Canavan disease (a leukodystrophy due to ASPA gene mutations) is rare but reported in consanguineous families (prevalence higher in certain communities with founder mutations), presenting in infancy with macrocephaly, hypotonia, developmental delay, seizures, and early death. High morbidity from underdiagnosis in rural areas, limited genetic testing access, delayed diagnosis leading to no curative treatment (supportive only). Per molecular pathology practices aligned with ICMR and Indian Academy of Pediatrics guidelines, the test employs PCR for ASPA gene mutation analysis over 1-2 days with high sensitivity/specificity, valuable for confirming diagnosis in suspected leukodystrophy. This diagnostic falls under genetic disorder screening and targets infants with macrocephaly/developmental delay, addressing accurate detection for genetic counseling and family planning. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing recurrence in families. Its whole blood-based approach ensures reliable detection.**Other Names**: Canavan Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: ASPA gene identified in 1990s; in India, reported in genetic disorder registries.**Purpose**: The test screens for 2 parameters including ASPA gene mutation to guide Canavan disease diagnosis, confirm leukodystrophy, inform counseling.**Test Parameters**: 1. ASPA Gene Mutation, 2. Canavan Disease Marker.**Pretest Condition**: No fasting required; patients should report macrocephaly, hypotonia, developmental delay in infants.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Parents should provide details on infant head size, motor delay, seizures, consanguinity, family neurological history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated disease including progression, benefits of diagnosis for counseling, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive mutation indicates Canavan disease, necessitating specialist input. Negative may require follow-up if symptoms suggestive.**Specialist Consultation**: Pediatric neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: MRI brain, NAA levels for confirmation.**Test Limitations**: May miss rare variants; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Leukodystrophy Studies India 2023. |
